Lyell Immunopharma (NASDAQ:LYEL - Get Free Report)'s stock had its "neutral" rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $1.00 price objective on the stock. HC Wainwright's price objective indicates a potential upside of 6.84% from the stock's previous close.
Lyell Immunopharma Stock Performance
NASDAQ:LYEL traded up $0.01 during mid-day trading on Monday, hitting $0.94. 3,455,110 shares of the stock were exchanged, compared to its average volume of 969,161. The firm's 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.80. The stock has a market capitalization of $238.62 million, a price-to-earnings ratio of -1.03 and a beta of -0.53. Lyell Immunopharma has a fifty-two week low of $0.86 and a fifty-two week high of $3.26.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. The company had revenue of $0.01 million during the quarter. On average, analysts predict that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.
Hedge Funds Weigh In On Lyell Immunopharma
Hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC lifted its position in shares of Lyell Immunopharma by 9.3% during the 1st quarter. ProShare Advisors LLC now owns 48,986 shares of the company's stock valued at $109,000 after acquiring an additional 4,170 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Lyell Immunopharma by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company's stock worth $68,000 after purchasing an additional 19,287 shares during the period. SG Americas Securities LLC grew its stake in Lyell Immunopharma by 78.1% during the third quarter. SG Americas Securities LLC now owns 57,566 shares of the company's stock worth $79,000 after buying an additional 25,247 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Lyell Immunopharma by 197.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company's stock valued at $58,000 after buying an additional 26,635 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Lyell Immunopharma in the 1st quarter valued at approximately $64,000. Institutional investors own 66.05% of the company's stock.
About Lyell Immunopharma
(
Get Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Further Reading
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
